These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 31327828)

  • 41. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
    Feng D; Guan Y; Liu M; He S; Zhao W; Yin B; Liang J; Li Y; Wang J
    Front Immunol; 2021; 12():608292. PubMed ID: 34135884
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Advances in Hyperprogressive Disease in Patients 
with Advanced Non-small Cell Lung Cancer Treated with Immunotherapy].
    Yao S; Shi K; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):271-278. PubMed ID: 33910275
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy.
    Okeya K; Kawagishi Y; Muranaka E; Izumida T; Tsuji H; Takeda S
    Intern Med; 2019 Nov; 58(22):3295-3298. PubMed ID: 31327828
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A case of pulmonary adenocarcinoma showing rapid progression of peritoneal dissemination after immune checkpoint inhibitor therapy.
    Shinozaki T; Iwami E; Ikemura S; Matsuzaki T; Nakajima T; Hashimoto K; Terashima T
    BMC Cancer; 2018 May; 18(1):620. PubMed ID: 29855288
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Psuedoprogression mimicking hyperprogressive disease after pembrolizumab treatment in a patient with lung cancer.
    Hashimoto K; Kaira K; Kawasaki T; Yamaguchi O; Kagamu H
    Lung Cancer; 2020 Jan; 139():221-223. PubMed ID: 31806361
    [No Abstract]   [Full Text] [Related]  

  • 46. Histologic transformation of lung cancer during pembrolizumab therapy: A case report.
    Si X; You Y; Zhang X; Wang H; Wang M; Zhang L
    Thorac Cancer; 2020 Mar; 11(3):793-796. PubMed ID: 31944570
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hyperprogression after first dose of immunotherapy in a patient with radioresistant metastasis from nonsmall cell lung cancer.
    Bosch-Barrera J; Oliva E; Sais E; Vásquez CA; Roselló A; Menéndez JA
    Anticancer Drugs; 2019 Nov; 30(10):1067-1070. PubMed ID: 31567311
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bilateral lung cancer showing various responses to immune checkpoint inhibitors: A case report.
    Kodama H; Ibe T; Inoue R; Shimada T; Ishii H; Hamamoto Y
    Cancer Rep (Hoboken); 2020 Oct; 3(5):e1272. PubMed ID: 32783372
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation.
    Abdallah N; Nagasaka M; Abdulfatah E; Shi D; Wozniak AJ; Sukari A
    Lung Cancer (Auckl); 2018; 9():85-90. PubMed ID: 30498383
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hyperprogressive disease: recognizing a novel pattern to improve patient management.
    Champiat S; Ferrara R; Massard C; Besse B; Marabelle A; Soria JC; Ferté C
    Nat Rev Clin Oncol; 2018 Dec; 15(12):748-762. PubMed ID: 30361681
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
    Paz-Ares L; Luft A; Vicente D; Tafreshi A; Gümüş M; Mazières J; Hermes B; Çay Şenler F; Csőszi T; Fülöp A; Rodríguez-Cid J; Wilson J; Sugawara S; Kato T; Lee KH; Cheng Y; Novello S; Halmos B; Li X; Lubiniecki GM; Piperdi B; Kowalski DM;
    N Engl J Med; 2018 Nov; 379(21):2040-2051. PubMed ID: 30280635
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
    Ferrara R; Mezquita L; Texier M; Lahmar J; Audigier-Valette C; Tessonnier L; Mazieres J; Zalcman G; Brosseau S; Le Moulec S; Leroy L; Duchemann B; Lefebvre C; Veillon R; Westeel V; Koscielny S; Champiat S; Ferté C; Planchard D; Remon J; Boucher ME; Gazzah A; Adam J; Bria E; Tortora G; Soria JC; Besse B; Caramella C
    JAMA Oncol; 2018 Nov; 4(11):1543-1552. PubMed ID: 30193240
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.
    Postow MA; Sidlow R; Hellmann MD
    N Engl J Med; 2018 Jan; 378(2):158-168. PubMed ID: 29320654
    [No Abstract]   [Full Text] [Related]  

  • 54. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
    Antonia SJ; Villegas A; Daniel D; Vicente D; Murakami S; Hui R; Yokoi T; Chiappori A; Lee KH; de Wit M; Cho BC; Bourhaba M; Quantin X; Tokito T; Mekhail T; Planchard D; Kim YC; Karapetis CS; Hiret S; Ostoros G; Kubota K; Gray JE; Paz-Ares L; de Castro Carpeño J; Wadsworth C; Melillo G; Jiang H; Huang Y; Dennis PA; Özgüroğlu M;
    N Engl J Med; 2017 Nov; 377(20):1919-1929. PubMed ID: 28885881
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.
    Lee JK; Lee J; Kim S; Kim S; Youk J; Park S; An Y; Keam B; Kim DW; Heo DS; Kim YT; Kim JS; Kim SH; Lee JS; Lee SH; Park K; Ku JL; Jeon YK; Chung DH; Park PJ; Kim J; Kim TM; Ju YS
    J Clin Oncol; 2017 Sep; 35(26):3065-3074. PubMed ID: 28498782
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Small cell lung cancer transformation during immunotherapy with nivolumab: A case report.
    Imakita T; Fujita K; Kanai O; Terashima T; Mio T
    Respir Med Case Rep; 2017; 21():52-55. PubMed ID: 28393006
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.
    Kato S; Goodman A; Walavalkar V; Barkauskas DA; Sharabi A; Kurzrock R
    Clin Cancer Res; 2017 Aug; 23(15):4242-4250. PubMed ID: 28351930
    [No Abstract]   [Full Text] [Related]  

  • 58. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.
    Champiat S; Dercle L; Ammari S; Massard C; Hollebecque A; Postel-Vinay S; Chaput N; Eggermont A; Marabelle A; Soria JC; Ferté C
    Clin Cancer Res; 2017 Apr; 23(8):1920-1928. PubMed ID: 27827313
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.